Evaluation of Ciprofloxacin and Levofloxacin Disk Diffusion and Etest Using the 2019 Enterobacteriaceae CLSI Breakpoints-Reference-Cited by-同舟云学术

Evaluation of Ciprofloxacin and Levofloxacin Disk Diffusion and Etest Using the 2019 Enterobacteriaceae CLSI Breakpoints

Published:2019-03 Issue:3 Volume:57 Page:
ISSN:0095-1137
Container-title:Journal of Clinical Microbiology
language:en
Short-container-title:J Clin Microbiol

Author:

Humphries Romney M.¹²,Hindler Janet A.³,Shaffer Keith⁴,Campeau Shelley A.¹

Affiliation:

1. Accelerate Diagnostics, Tucson, Arizona, USA

2. University of Arizona, Department of Pathology, Tucson, Arizona, USA

3. Los Angeles Department of Public Health, Los Angeles, California, USA

4. UCLA Clinical Microbiology Department, Los Angeles, California, USA

Abstract

In 2019, the Clinical and Laboratory Standards Institute (CLSI) published revisions to the Enterobacteriaceae ciprofloxacin and levofloxacin breakpoints. We evaluated the performance of disk diffusion and Etest compared to that of reference broth microdilution by use of the revised breakpoints.

Publisher

American Society for Microbiology

Subject

Microbiology (medical)

Link

https://journals.asm.org/doi/pdf/10.1128/JCM.01797-18

Reference8 articles.

1. Chantell C, Humphries RM, Lewis JII. 2019. Ciprofloxacin, and levofloxacin Enterobacteriaceae and Pseudomonas aeruginosa rationale document, in press. Clinical and Laboratory Standards Institute, Wayne, PA.

2. Clinical and Laboratory Standards Institute. 2018. Performance standards for antimicrobial disk susceptibility tests. M02 standard, 13th ed. Clinical and Laboratory Standards Institute, Wayne, PA.

3. Clinical and Laboratory Standards Institute. 2018. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. M07 standard, 11th ed. Clinical and Laboratory Standards Institute, Wayne, PA.

4. Clinical and Laboratory Standards Institute. 2018. Performance standards for antimicrobial susceptibility testing. M100 standard, 28th ed. Clinical and Laboratory Standards Institute, Wayne, PA.

5. Clinical and Laboratory Standards Institute. 2018. Development of in vitro susceptibility testing criteria and quality control parameters. M23 guideline, 4th ed. Clinical and Laboratory Standards Institute, Wayne, PA.

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Intermethod comparability analyses of gepotidacin antimicrobial susceptibility tests using a large collection of globally collected Escherichia coli and Staphylococcus saprophyticus clinical isolates;Diagnostic Microbiology and Infectious Disease;2024-03

2. Development and evaluation of ciprofloxacin local controlled release materials based on molecularly imprinted polymers;European Journal of Pharmaceutics and Biopharmaceutics;2024-02

3. Antibacterial and anti-biofilm properties of carvacrol alone and in combination with cefixime against Escherichia coli;BMC Microbiology;2023-03-03

4. Piper nigrum Fruit Extract as an Antibiotic Resistance Reversal Agent in MDR Bacteria;Applied Sciences;2022-12-07

5. Correlation of Vitek 2 and Agar dilution for levofloxacin susceptibility testing and clinical outcomes of Enterobacterales bacteremia with 2019 CLSI breakpoints;Diagnostic Microbiology and Infectious Disease;2022-12